Pathology Laboratories Market Size, Share, Growth, Trends | Report 2022-2030
The global pathology laboratories market was estimated at USD 311.3 billion in 2021 and it is expected to surpass around USD 612.41 billion by 2030, poised to grow at a CAGR of 7.81% from 2022 to 2030.
The major factors driving the industry include increasing life expectancy, the development of healthcare infrastructure in developing nations, favoring reimbursement, and rising demand for routine medical check-ups.
In addition, the advancement of technology is altering the dynamics of diagnosis. Innovative technologies have made Point of Care Testing(POCT) devices portable and improved sampling techniques, making diagnostic services more accessible and efficient. Several advancements are expected to transform the industry by steering patient care through quality, speed, efficiency, and scalability. The healthcare system is progressively emphasizing the importance of pathological & diagnostic labs in becoming a greater clinical decision-making engine, assisting physicians in making inferences and diagnosing as well as monitoring patients more quickly and accurately.
The COVID-19 pandemic has resulted in higher demand for pathology/diagnostic labs as the testing for COVID-19 was necessary during the pandemic. The rapid rise of COVID-19 infections has resulted in increased funding and testing, which has boosted the overall market growth. For instance, the (NIH) National Institutes of Health in the United States announced in September 2020 that it would grant USD 129.3 million in funding to nine organizations including, Maxim Biomedical Inc., MatMaCorp, MicroGEM International, & others, for scaling-up manufacturing assistance to a new set of COVID-19 testing technologies as component of its initiative to boost diagnostics in the region.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 311.3 billion |
| Revenue Forecast by 2030 | USD 612.41 billion |
| Growth rate from 2022 to 2030 | CAGR of 7.81% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Type, testing services, end-use, region |
| Companies Covered |
Quest Diagnostics Incorporated; Eurofins Scientific; Laboratory Corporation of America Holdings; Exact Sciences Laboratories LLC; Spectra Laboratories; SYNLAB International GmbH; Sonic Healthcare Limited; Dr. Lal Path Labs; Metropolis Healthcare; Kingmed Diagnostics; Healius Limited; BioReference.; Centro de Diagnósticos; Falco Holdings; Unilabs |
Type Insights
The global pathology laboratories market is categorized into hospital-based, standalone labs, and diagnostic chains. Hospital-based labs accounted for the largest market share in 2021 The hospital-based laboratories perform more tests compared to other types of laboratories, giving them an edge over other labs. In addition, the presence of various government regulations and insurers is one of the major drivers of competition between standalone labs and hospital-based labs.
Standalone labs facilitate serval pathological tests at a lower price compared to hospital-based labs. For instance, according to a pricing analysis by Amino, the cost of an MRI at a hospital-based pathology lab is more than twice as compared to a standalone diagnostic center. The growing demand for general medical check-ups as a result of increased awareness is boosting the scope for standalone labs.
Diagnostic chains offer a patient-centric array of tests in the form of annual packages or bundled tests. The services offered across the region or country are similar at all centers and thus these chain focus on maintaining by obtaining accreditations from organizations such as the International Organization of Standardization (ISO) certification, National Accreditation Board for Testing and Calibration Laboratories (NABL), and College of American Pathologists (CAP) accreditation.
Testing Services Insights
Based on the testing services, the diagnostic labs market is segmented into general physiological & clinical tests, imaging & radiology tests, esoteric tests, and COVID-19 tests. In 2021, general physiological & clinical tests held the largest market share. However, there was significant demand for COVID-19 tests due to the peak of the second wave, as it was mandatory to have COVID-19 testing pre & post-travel. The resumption of offices, factories, etc. also required mandatory COVID-19 testing. With the home COVID-19 test available in the majority of countries, the demand for RT PCR tests is no longer mandatory, thus the market for COVID-19 tests is expected to drastically decline over the forecast period.
The imaging & radiology tests segment is expected to witness lucrative growth during the forecast period. This can be attributed to the increasing demand for early diagnosis of chronic ailments, the growing scope of clinical applications & technological advancement. X-ray imaging is the most common and is the most preferred test among all diagnostic imaging testing. The high incidence of road accidents and aging orthopedic disorders is boosting the demand for x-rays. The application of X-rays in the detection of lung infection, enlarged liver, and other diseases has led to high demand. Other diagnostic imaging tests include ultrasound, Magnetic Resource Imaging (MRI), Computed Tomography (CT) scans, Positron Emission Tomography (PET) scans, nuclear imaging, and mammography.
The esoteric tests segment is expected to witness the fastest growth during the forecast period. Esoteric testing includes infectious diseases testing, endocrinology testing, oncology testing, genetics testing, toxicology testing, immunology testing, and neurology testing. Infectious diseases testing & oncology are expected to have the highest demand owing to the rise of infectious diseases & cancer among the population. The criticality of early diagnosis of cancer and other life-threatening diseases is expected to increase the demand for these tests.
End Use Insights
Based on end use, the market is segmented into physician referrals, walk-ins, and corporate. Physician referrals accounted for the largest revenue share in 2021. This can be attributed to the fact that around 70% of all medical decisions made by physicians are based on pathological and diagnostic test results. The growth of target diseases among all ages is anticipated to stimulate segment growth.
The corporate segment is expected to witness lucrative growth during the forecast period due to improvements in employee benefit policies such as annual medical check-ups in the corporate sector. Furthermore, government bodies in many countries are also making it mandatory for companies to have health check-ups of employees. For Instance, in November 2020 the union government of India proposed a new set of labor rules making it mandatory for companies to have an annual check-up of employees above 40 years of age. The key market players are coming up with customized packages for corporate clients. Quest diagnostics provided COVID-19 testing & symptom check for employers across the U.S. looking forward to resuming offices post-pandemic.
The walk-in segment will be driven by the rise in awareness regarding health and wellness, resulting in more individuals opting for routine check-ups. A population above 50 is the target patient population for this segment. The growing geriatric population & increasing life expectancy is expected to further drive the segment growth, especially in Asia & Europe where the aging population is very high.
Region Insights
North America held the largest market share in 2021. As per the Centers for Disease Control and Prevention (CDC), four in every ten American adults are having multiple chronic diseases. Cardiovascular disorders are the most common chronic ailment & the leading cause of death in the U.S. accounting for 1 in 3 deaths. The CDC is focusing on the diagnosis & prevention of risk factors like cholesterol & blood pressure causing heart problems.
Asia-Pacific is expected to fastest growth during the forecast period from 2022 to 2030 due to the availability of cost-effective pathology tests in the region. According to the facts published by the Asian Diabetes Prevention Initiative, 60% of diabetics globally are Asians. China & India have the highest diabetes prevalence with 113.9 & 65.1 million adults having diabetes in respective nations. Asians have reported 3-5% more body fat compared to European’s making them more prone to diabetes. Diabetes may result in complications like heart issues, kidney damage, eye & foot damage, and hearing impairment. The Asian Diabetes Prevention Initiative is thus promoting the early diagnosis of diabetes to reduce the burden of healthcare expenditure in developing countries.
Europe is expected to witness lucrative growth during the forecast period due to the increasing adoption of advanced imaging techniques, a higher proportion of the elder population & rising demand for esoteric testing. The high prevalence of cancer in Denmark & France is creating more opportunities for oncology testing services. As per the World Cancer Research Fund International, Denmark, France, Belgium, Hungary, Ireland; & Netherlands have an average cancer rate of 300 per 10,000 people, indicating the high prevalence of oncology & the need for diagnosis. However, the high cost of advanced imaging devices & unfavorable reimbursement scenario in the region is restricting the entry of new players.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pathology Laboratories Market
5.1. COVID-19 Landscape: Pathology Laboratories Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pathology Laboratories Market, By Type
8.1. Pathology Laboratories Market, by Type, 2022-2030
8.1.1 Hospital-based
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Standalone Labs
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Diagnostic Chains
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Pathology Laboratories Market, By Testing Services
9.1. Pathology Laboratories Market, by Testing Services, 2022-2030
9.1.1. General Physiological & Clinical Tests
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Imaging & Radiology Tests
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Esoteric Tests
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. COVID-19 Tests
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Pathology Laboratories Market, By End Use
10.1. Pathology Laboratories Market, by End Use, 2022-2030
10.1.1. Physician Referrals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Walk-ins
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Corporate
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Pathology Laboratories Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.1.3. Market Revenue and Forecast, by End Use (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End Use (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End Use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.2.3. Market Revenue and Forecast, by End Use (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End Use (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End Use (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End Use (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End Use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.3.3. Market Revenue and Forecast, by End Use (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End Use (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End Use (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End Use (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End Use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.4.3. Market Revenue and Forecast, by End Use (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End Use (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End Use (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End Use (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End Use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.5.3. Market Revenue and Forecast, by End Use (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End Use (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Testing Services (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End Use (2017-2030)
Chapter 12. Company Profiles
12.1. Quest Diagnostics Incorporated
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Eurofins Scientific
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Laboratory Corporation of America Holdings
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Exact Sciences Laboratories LLC
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Spectra Laboratories
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. SYNLAB International GmbH
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Sonic Healthcare Limited
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Dr. Lal Path Labs
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Metropolis Healthcare
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Kingmed Diagnostics
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers